Dr. David H. Lindner, DO
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Medical school
- Des Moines University of Osteopathic Medicine and Health Sciences (1989)
- Years since graduation
- 37
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 704
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1989Medical school: Des Moines University of Osteopathic Medicine and Health Sciences
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
FL license OS0006979 -
Critical Care Medicine (Internal Medicine) Physician
FL license OS0006979
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Naples Community Hospital Naples, FL
- Physicians Regional Medical Center - Pine Ridge Naples, FL
Medical groups
- Nchmd Inc (510 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 704
- Services billed
- 3,127
- Patients’ average age
- 78
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 366 | 204 |
| Established patient office or other outpatient visit, 30-39 minutes | 280 | 206 |
| Test to examine how well the lungs exchange gases | 265 | 253 |
| Test to determine lung volumes using sensors | 263 | 251 |
| Test to measure rate of airflow | 210 | 194 |
| Critical care, first 30-74 minutes | 206 | 100 |
| Insertion of needle into vein for collection of blood sample | 202 | 130 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 201 | 125 |
| Test for exercise-induced lung stress | 180 | 131 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 108 | 81 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Opsumit (macitentan) | 272 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Naples, FL | 249 |
| Uptravi (selexipag) | 140 |
| Adempas (riociguat) | 134 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Naples, FL | 120 |
| Sildenafil Citrate Other prescribers in Naples, FL | 105 |
| Ambrisentan | 104 |
| Anoro Ellipta (umeclidinium brm/vilanterol tr) Other prescribers in Naples, FL | 79 |
| Breo Ellipta (fluticasone/vilanterol) Other prescribers in Naples, FL | 64 |
| Prednisone Other prescribers in Naples, FL | 61 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 14 companies reported 49 payments worth $5,453 in total to this clinician.
| Intuitive Surgical, Inc. | $2,092 |
|---|---|
| Pulmonx Corporation | $2,055 |
| Actelion Pharmaceuticals US, Inc. | $380 |
| Insmed, Inc. | $158 |
| Grifols Shared Services North America, Inc. | $149 |
| Lilly USA, LLC | $110 |
| Galvanize Therapeutics, Inc | $94.63 |
| Pinnacle Biologics, Inc | $92.45 |
| Food and Beverage | $2,142 |
|---|---|
| Consulting Fee | $1,700 |
| Travel and Lodging | $1,510 |
| Education | $99.95 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Pulmonx Corporation May 21, 2025 | Consulting Fee ZEPHYR ENDOBRONCHIAL VALVE; PULMONX CHARTIS TABLET CONSOLE; CHARTIS CATHETER · PULMONOLOGY | $1,500 |
| Intuitive Surgical, Inc. Aug 19, 2025 | Travel and Lodging Da Vinci Surgical System · SURGERY · travel to CHICAGO, IL · in-kind | $745 |
| Intuitive Surgical, Inc. Sep 8, 2025 | Travel and Lodging Da Vinci Surgical System · SURGERY · travel to CHICAGO, IL · in-kind | $633 |
| Pulmonx Corporation Oct 8, 2025 | Consulting Fee ZEPHYR ENDOBRONCHIAL VALVE; PULMONX CHARTIS TABLET CONSOLE; CHARTIS CATHETER · PULMONOLOGY | $200 |
| Pulmonx Corporation May 21, 2025 | Travel and Lodging ZEPHYR ENDOBRONCHIAL VALVE; PULMONX CHARTIS TABLET CONSOLE; CHARTIS CATHETER · PULMONOLOGY · travel to WAHINGTON, DC | $114 |
| Actelion Pharmaceuticals US, Inc. May 15, 2025 | Education OPSUMIT; UPTRAVI · Cardiology · in-kind | $99.95 |
| Intuitive Surgical, Inc. Aug 19, 2025 | Travel and Lodging Da Vinci Surgical System · SURGERY · travel to CHICAGO, IL · in-kind | $19.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $48,143 in research payments for these studies, mostly to the institutions running them.
- Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection
United Therapeutics Corporation · Completed · NCT05776225 - DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
United Therapeutics Corporation · Recruiting · NCT06388421 - Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex
Insmed, Inc. · Completed · NCT04677569
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.